Breast cancer is the most common cancer of adolescents and young adult (AYA) women aged 15 to 39 years, accounting for 5.6% of all invasive breast cancer in women. In comparison with older women, AYAs are more likely to have familial cancer predisposition genes, larger breast tumors, unfavorable biological characteristics, distant metastatic disease at diagnosis, and adverse outcome. Endocrine therapy and some chemotherapy recommendations differ between young and older women. AYAs require coordinated multidisciplinary care, treatment regimens that minimize late effects such as premature menopause and osteoporosis, and proactive management of psychological and sexual health during and after cancer treatment.
INTRODUCTION
This article updates our 2009 review of breast cancer in young women, 1 
EPIDEMIOLOGY
Breast cancer is the most common cancer among women worldwide. 4 It is the most common cancer among AYAs in the United States (US), The percentage of all cancer that is breast cancer increases rapidly among AYA women during the third and fourth decades of life, from 2% at age 20 to more than 40% by age 40 ( Figure 1 , lower panel). The abrupt increase at age 40 is attributable to routine screening mammography. Breast cancer incidence is similar among AYA women in both developed and developing countries. 6 Breast cancer in males is rare and has an older age predominance. There are 30 to 40 new cases annually in AYA males, comprising 0.1% of all cancer and 2.6% of breast cancer in AYAs. Breast cancer in males is not further reviewed in this article.
In the US, the incidence of invasive breast cancer has slightly increased among AYA women since 1992 (SEER). Between 1990 and 2008, the incidence of breast cancer increased by about 1.2% per year among European in AYA women, with the greatest increases in women under 35. 7 Figure 3 shows the incidence trends since 1975 by age and extent of disease at diagnosis. The incidence of local and regional disease has remained stable among AYAs, but distant disease has increased and the rate of increase is rising (upper panel of AYAs have distant (stage IV) disease at diagnosis. 9 Breast cancer incidence varies according to race and ethnicity in US AYAs. In comparison to young white women, black women aged < 35 have a higher incidence of invasive breast cancer and three times greater breast cancer mortality (SEER and National Center for Health Statistics). 10, 11 In contrast, breast cancer is less frequent among Native American women of all ages compared with the general US population. 12 Advanced disease at diagnosis is more common among AYA black, Hispanic, and Native American women, and in women of all ages with low socioeconomic status. 13 
Hormonal
Breast cancer risk in AYAs increases with early menarche, oral contraceptive use 10 (particularly for teenage BRCA1 carriers), 21 anovulatory infertility, 22 later age (>30 years) at first birth, and for several months following the delivery of a child. 23 Breastfeeding decreases the risk for AYA breast cancer. 24 
Personal and lifestyle
Prior mantle irradiation 25 and alcohol consumption 26 are wellestablished risk factors for breast cancer at all ages. A >10 pack-year smoking history increases the risk of estrogen receptor (ER)-positive breast cancer by 1.6-fold among women aged 20 to 44. 27 Although low body mass index (BMI) increases risk 10 for AYA breast cancer, substantial weight gain (BMI increase of ≥10 kg/m 2 ) after age 18 also raises the risk of ER-negative breast cancer by 2-fold. 28 The triad of high caloric intake, inactivity, and obesity increases risk in premenopausal women, 29 whereas regular vigorous exercise decreases risk. 30, 31 A diet high in energy-rich foods, such as red meat or fast food, increases premenopausal breast cancer risk. 4, 10, 32, 33 In contrast, a whole food, plant-based, low-energy density diet reduces the risk for AYA breast cancer. 4, 32, 33 Substituting legumes for one serving of meat per day lowers breast cancer risk by 19% among premenopausal women. 34 High mammographic density is a risk factor for breast cancer at all ages. 35 Breast density in premenopausal women is affected by dietary intake of alcohol, vitamin D, and calcium, 36 by IL-6 levels, 37 and by dehydroepiandrosterone sulfate (DHEAS) levels in early adolescence. 38 Low vitamin D intake is associated with increased risk for premenopausal breast cancer and with the development of larger, higher grade tumors. 39 
CLINICOPATHOLOGIC FEATURES

Subtype and grade
The distribution of breast cancer subtype and grade changes with age, 40 with more aggressive phenotypes among AYA compared with older women. Among 185 premenopausal women with invasive breast cancer <50 years of age, women <35 had a greater risk of developing of ER-negative, progesterone receptor (PR)-negative, and pathologic grade 3 tumors, as well as vascular or lymphatic invasion. 41 Basallike and Her2-enriched breast tumors are more common in young compared with older women. 42 
Gene expression
Comprehensive gene expression profiling has the capacity to predict outcome and detect age-related differences in breast tumor biology.
Azim et al showed that, compared with older women, AYAs more frequently developed aggressive triple-negative tumors with stromalrelated signatures. Risk of relapse was also higher in AYAs, following adjustment for subtype, grade, tumor size, and nodal status. A candidate gene approach, adjusting for subtype, identified over 12 gene sets that were associated with young age. 43 Anders et al compared clinically annotated global gene expression data from >700 early-stage breast cancers within two cohorts (≤45 and ≥65 years). The younger group demonstrated differential expression of ER, PR, Her2/neu, and epithelial growth factor receptor (EGFR), and Gene Set Enrichment Analysis identified 367 significant gene sets enriched among the younger cohort. 44 However, after correction for subtype and clinicopathologic features such as tumor grade, age-related gene expression differences were no longer seen. 45 A subsequent study reported age-dependent expression of individual breast cancer genes, using a candidate gene approach and after correction for tumor grade and subtype. Compared with older women, AYAs had relative overexpression of BUB1, KRT5, and MYCN and underexpression of CXCL2. Within tumor subtypes, gene expression had an age-related impact on outcome. 46 Thus, age-related biological differences in breast tumors exist but may be largely driven by the higher frequency of aggressive basal-like and Her2-enriched subtypes among AYAs. The underlying reason for overrepresentation of aggressive subtypes among AYAs is not known and merits research.
TREATMENT AND MANAGEMENT
Early-stage disease
AYAs often choose breast-conserving cancer surgery for reasons including body image, lactation, sexual function, and quality of life.
However, the risk of local breast cancer recurrence after conservative surgery is 9-fold higher among women diagnosed <age 35 compared with >age 60. 47 Nevertheless, conservative surgery in young women has not been associated with a negative impact on survival. In AYAs, breast-conserving surgery should always be followed by radiation. Following mastectomy, adjuvant radiation is used more often in AYAs compared with older women. 48 BRCA mutation carriers may have a higher incidence of radiation-induced malignancies. 49 Because of their higher risk for distant recurrence, adjuvant systemic therapies are usually warranted in AYAs with breast cancer. 50 ER-negative tumors, which benefit more from chemotherapy, are more frequent in AYAs than older women. Among patients <50 years old, use of adjuvant chemotherapy reduces the relative risk (RR) of recurrence by 35% and of death by 27%. 51 Choice of chemotherapy regimen is based on stage and clinical subtype.
For ER-positive early-stage breast cancers, adjuvant endocrine therapy reduces the risk of recurrence by approximately 50% in young women. 52 The ATLAS and aTTom trials found that 10 years of tamoxifen were superior to five for all age groups. 53, 54 Adding ovarian suppression to tamoxifen has the most potential to prevent recurrence among AYAs aged <35 and premenopausal patients who receive chemotherapy, and addition of an aromatase inhibitor even further reduces recurrence risk. 55 Both tamoxifen and aromatase inhibitors may cause menopausal symptoms such as hot flashes. 56 
Metastatic disease
In both AYAs and older women, metastatic breast cancer is treated with sequential systemic therapy regimens, with each regimen aiming to palliate symptoms and slow disease progression for as long as possible. Premenopausal women with ER-positive disease should also either receive an ovarian-suppressing medication for the duration of endocrine therapies (including tamoxifen, aromatase inhibitor, and fulvestrant) or else undergo bilateral salpingoophorectomy. [57] [58] [59] 
OUTCOMES
Age disparities
During 2012 to 2014 in the US, the individual average risk of a woman dying from breast cancer by the age of 40 was 1 in 1925 and the probability 0.052% (SEER). Age <35 years at diagnosis is an independent predictor of time to recurrence (RR 1.70) and overall mortality (RR, 1.50). 60 Following a diagnosis of early-stage breast cancer, AYAs are 39% more likely to die compared with older women. 61 For all stages, survival rates are lower among AYAs compared with older women diagnosed with breast cancer. Of all age groups, women aged 40 to 55 have the best 5-year relative survival for stage II-IV disease ( Figure 4) . 62 Among AYAs, survival is inversely proportional to age at every stage, with the poorest survival rates among the women diagnosed at the youngest ages. Stage IV breast cancer has the worst prognosis by far (Figure 4 , lower panel).
For every histologic subtype of breast cancer, survival is worse for AYAs than for older women. This outcome disparity is most pronounced for invasive ductal carcinoma, but it is present for medullary, inflammatory and lobular breast cancer, as well as Paget's disease of the breast (SEER). 63 AYAs have inferior outcomes with all subgroups of hormone receptor expression. For patients with ER-negative tumors, incidence of relapse peaks at 2 years after therapy. For patients with ER-positive tumors, the incidence of relapse steadily declines over an 8-year period. 64 Since 1985, the improvement in the rate of breast cancer survival among AYA women has exceeded that of older women for all stages at diagnosis (SEER). The greatest relative gains have been in AYAs who present with distant disease, possibly due to improved strategies for palliative and supportive care.
Breast cancer outcomes for AYAs in Asia are not inferior to those of older women despite higher grade tumors and more advanced disease at diagnosis in younger patients. 65 This geographic variation in agerelated outcome differences could be related to either environmental or genetic factors.
Ethnic disparities
Among AYA women with breast cancer, African Americans have the worst survival rates, followed by white non-Hispanics, followed by was three times greater for white than for black AYA women in the US. 32 In the United Kingdom, blacks have worse outcomes than whites despite equal access to health care. 67 
Risk factors for death
Young age at diagnosis is a risk factor for death following local recur- patients with hormone-receptor-negative disease. 69 Germline mutations in PALB2 are associated with strong predisposition to early-onset breast cancer and inferior breast cancer survival. 70 Comorbid medical conditions may increase breast cancer mortality in AYAs. Among premenopausal breast cancer patients, obesity is associated with poor prognosis, 71 and type 2 diabetes mellitus 72 is associated with inferior disease-free survival, increased recurrence and metastasis compared with age-matched breast cancer patients without these conditions.
Second malignancies
Breast cancer is the most common secondary malignancy arising in females treated for childhood cancer. Risk is highest following chest radiation, anthracyclines, or alkylating agents. At-risk survivors should be managed according to the Children's Oncology Group breast cancer surveillance guidelines. 73 Contralateral breast cancer is the most common second malignancy by far in survivors of primary breast cancer, 74 and risk increases with younger age at diagnosis. Compared with women whose primary diagnosis occurred at age 40+, women initially diagnosed with breast cancer at age 29 or younger have an HR of 2.8 for the development of contralateral breast cancer. 75 Very early age at diagnosis (<30 years) was associated with a very high risk (RR > 30) compared with the general population. RR is 10.2 for women diagnosed between 30 and 34 years of age and 6.9 in women diagnosed between 35 and 39 years of age. In comparison, RR decreases to 1.1 for women diagnosed at 60 to 64 years of age. 76, 77 For women diagnosed between 15 and 44 years of age, the cumulative RR for developing a contralateral breast cancer is 5.4. 76, 77 Risk for contralateral breast cancer is significantly heightened in women diagnosed with breast cancer at age <45 years who have either a family history of bilateral breast cancer (RR 3.6) or a first-degree relative with breast cancer under age 45 (RR 2.5), compared with those without a family history of breast cancer. 78 For AYAs, radiotherapy following lumpectomy, compared with after mastectomy, imparts an additional 50% increased risk of contralateral breast cancer. 79 For all ages, adjuvant chemotherapy decreases the risk of contralateral breast cancer for five years following treatment, but not subsequently. 79 AYAs treated for breast cancer also have disproportionately high rates of myelodysplastic syndrome (RR 30.4) 80 and second malignancies in other sites, including bone, thyroid, ovary, colon, corpus uteri, lung, kidney, melanoma and nonmelanoma skin cancer, leukemia, and lymphoma. 77 
SPECIAL ISSUES FOR AYAs WITH BREAST CANCER
Fertility preservation
AYAs face potential long-term infertility resulting from breast cancer therapy, 81 and ASCO guidelines mandate counseling about this risk at the time of diagnosis. 82 Before the start of any systemic therapy, all AYAs with breast cancer should be offered referral to a reproductive endocrinologist for either embryo or oocyte cryopreservation. Preimplantation genetic diagnosis, selecting unaffected embryos for implantation, is an option for carriers of BRCA mutations or other cancer predisposition syndromes. 83 Ovarian suppression with goserelin during chemotherapy is an option for AYAs with hormone-receptor-negative breast cancer, decreasing the incidence long-term ovarian failure and possibly improving pregnancy outcomes. 84 
Inherited breast cancer
Genetic evaluation is an essential component of multidisciplinary care for AYAs with breast cancer and should be initiated promptly following diagnosis. Patients require both pretest counseling, to assess family history and evaluate risk, and posttest genetic counseling to accurately interpret test results. Because numerous genes may predispose AYAs to early-onset breast cancer, next-generation sequencing panels-which evaluate numerous genes simultaneouslyare preferable to single gene testing. 85 Women with familial breast cancer syndromes require individualized counseling, evidence-based recommendations regarding tumor surveillance and prophylactic mastectomy/oophorectomy, ongoing support for decision-making, and lifelong tumor surveillance. 86 
Pregnancy during and after breast cancer
Pregnant women who receive standard chemotherapies for breast cancer during the second and third trimesters have outcomes comparable with nonpregnant breast cancer patients. 87, 88 The desire for future pregnancy can affect selection of treatment protocol. One multicenter study showed that 19% of young breast cancer patients refused endocrine therapy, or chose one chemotherapy regimen over another, based on the wish to bear children in the future. 81 Pregnancy following a diagnosis of breast cancer does not impact mortality. A large meta-analysis showed a lower relative risk of death (RR = 0.59) among women who bore a child after a breast cancer diagnosis. 89 The POSITIVE study is prospectively evaluating outcomes of pregnancy following breast cancer.
Survivorship issues
When considering adjuvant endocrine therapy and chemotherapy, clinicians should consider the long-term impact of bone loss, including osteoporosis and potentially disabling fractures. Bisphosphonate therapy has the potential to reduce bone loss 90 and improve breast cancer outcome, 91 decreasing distant metastases and bone recurrences among postmenopausal women. 92 It is unclear if AYAs would derive similar benefit. Formal guidelines for bisphosphonate use in AYAs are eagerly awaited.
Most AYAs who survive breast cancer will live for decades following treatment and are at significant risk for second breast cancers and other malignancies. 93 Providers should proactively encourage AYA breast cancer survivors to adopt risk-reduction strategies, including regular vigorous exercise, limitation of alcohol, and a diet low in energy density and rich in plants. 4, 30, 31 
Psychosocial issues
AYAs are at significant risk for emotional and psychosocial sequelae during and after breast cancer treatment. They require age-specific psychosocial support, ideally in the context of coordinated multidisciplinary care teams. 94, 95 A retrospective study of >500 breast cancer survivors aged 25 to 50 years showed that long-term difficulties with emotional and social functioning increased with decreasing age at diagnosis. Younger breast cancer survivors experienced lower vitality and higher rates of depression. 90 Another study showed that, in comparison with both age-matched healthy controls and women who were older at diagnosis, AYAs who had completed adjuvant chemotherapy for breast cancer 3 to 8 years earlier were at increased risk for difficulties with anxiety, sleep, marital satisfaction, and body image. 96 Concerns about fertility, sexuality, and body image, disruptions in peer and romantic relationships, financial and occupational difficulties, and death from cancer are more pronounced in AYAs than older survivors and may contribute to distress. 81, 97, 98 Interventions to enhance psychosocial outcomes are currently being developed, including mindfulness meditation and online supports for patients and their families. 99, 100 
LIMITATIONS
Young women have only recently been studied as a specific subgroup of breast cancer patients. There are few large-scale, prospective studies focusing on this population. We present emerging data on statistically significant risk factors and evidence-based treatment recommendations for breast cancer in AYAs.
CONCLUSION
Breast cancer is the most common malignancy among AYA women, who tend to present with more aggressive breast cancer subtypes and have worse outcomes compared with older women with breast cancer. Optimal care for this population requires a multidisciplinary team to maximize outcome, preserve quality of life, and foster healthy survivorship. Multidisciplinary care algorithms for AYAs with breast cancer should include upfront investigation of familial cancer susceptibility, tailoring of the medical regimen to maximize fertility in patients who desire future children, management of reproductive issuesincluding the potential for posttreatment infertility, premature ovarian failure, or pregnancy, counseling for psychosocial and sexual issues, and long-term survivorship care.
